Status:
COMPLETED
THRIVE Use in Pediatric Populations- Multi Site
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Nationwide Children's Hospital
Ann & Robert H Lurie Children's Hospital of Chicago
Conditions:
Oxygen Deficiency
Desaturation of Blood
Eligibility:
All Genders
Up to 18 years
Phase:
NA
Brief Summary
THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange) refers to the use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia...
Eligibility Criteria
Inclusion
- Pediatric patients less than 18 years of age undergoing general anesthesia for procedures or surgeries
Exclusion
- Pregnancy
- Absence of parent or legal guardian able to provide written consent for study participation
- Anatomical or surgical contraindications (epistaxis, basilar skull fractures or abnormalities, nasal surgery or obstruction, nasal fractures, nasal vascular abnormalities), tracheostomy tube
- Emergent surgery for which application of HFNC might delay surgery or might result in increased aspiration risk.
Key Trial Info
Start Date :
October 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 19 2024
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT04322994
Start Date
October 21 2020
End Date
January 19 2024
Last Update
March 27 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Lucile Packard Children's Hospital Stanford
Palo Alto, California, United States, 94304
2
Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
3
Massachussetts Eye and Ear Harvard Medical School
Boston, Massachusetts, United States, 02114
4
Cincinnati Children's Hospital
Cincinnati, Ohio, United States, 45229